ライフサイエンスコーパス: high-grade tumor

1 various grades of tumor, including low- and high-grade tumors.

2 ry for malignant progression of low-grade to high-grade tumors.

3 emonstrated a decrease in CHK2 expression in high-grade tumors.

4 y the levels of HOIL-1L were associated with high-grade tumors.

5 h PMLS518 phosphorylation, PML turnover, and high-grade tumors.

6 oes, one would expect a similar reduction in high-grade tumors.

7 ened the association of E-cadherin loss with high-grade tumors.

8 of 0.91 for discriminating low-grade versus high-grade tumors.

9 activated in a substantial fraction of human high-grade tumors.

10 rimary or adjuvant therapy for localized but high-grade tumors.

11 prominent among PEGA genes overexpressed in high-grade tumors.

12 nd to monitor anaplastic transformation into high-grade tumors.

13 T2 by serine phosphorylation associates with high-grade tumors.

14 sting a novel function for AQP expression in high-grade tumors.

15 immunohistochemistry and FISH studies in 111 high-grade tumors.

16 hypoxic cells is relatively low, even in the high-grade tumors.

17 the disease but increases the proportion of high-grade tumors.

18 ereas deletion of ink4a/arf is found only in high-grade tumors.

19 heterozygous for ink4a/arf or p53 developed high-grade tumors.

20 /g/min; P < 0.02), and K(FLT) was higher for high-grade tumors (0.018 +/- 0.008 mL/g/min, n = 9) than

21 %, respectively), and patients who had fewer high-grade tumors (13% v 64%, respectively) or right-sid

22 02) and tended to be higher in patients with high-grade tumors (18.8 versus 8.5; P = 0.090).

23 sk, 2.71 [95% CI, 2.26-3.24]; P < .001), and high-grade tumor (45.1% vs 18.2%; relative risk, 3.01 [9

24 A larger proportion of high-grade tumors (53.8% vs. 44.3%) and lesions over 10

25 women presenting with large (4.4 +/- 2.0 cm) high-grade tumors (83%) in advanced stages (72% node pos

26 ors (median, 12 v 8 cm), more frequently had high-grade tumors (90% v 64%), and were younger (median

27 , (18)F-FDG was positive in all intermediate/high-grade tumors (95% confidence interval [CI], 97.3%-1

28 sed expression of p27Kip1 is associated with high grade tumors and an unfavorable prognosis in severa

29 F3 gene has been shown to be up-regulated in high-grade tumors and its down-regulation leads to loss

30 calization may be an additional indicator of high-grade tumors and poor prognosis in cancer.

31 , colon, and breast cancer cell lines and in high-grade tumors and that their expression correlates w

32 Patients with high-grade tumors and/or LVI may have 10-year RFS rates

33 esh astrocytoma operative specimens (low and high grade tumors) and seven primary human astrocytoma c

34 oss of chromosome 4 occurs preferentially in high-grade tumors, and that gains of 3q26-qter, 8q24-qte

35 e molecular pathogenesis of low-grade versus high-grade tumors appears to be largely distinct.

36 itial resection, age less than 50 years, and high-grade tumors are candidates for investigational adj

37 High-grade tumors are currently treated with hormone the

38 tients who develop local recurrence and have high-grade tumors as being at high risk for systemic dis

39 atio may be a novel indicator of aggressive, high-grade tumor behavior, and control of JAB1 could be

40 Seven patients showed progression to high-grade tumors between 6 and 36 months (mean, 22.3 mo

41 In high-grade tumors, both tumor cells and tumor-associated

42 pressed in tumor tissue, and associated with high-grade tumor cells and poor patient prognosis.

43 aporin (AQP) water channels are expressed in high-grade tumor cells of different tissue origins.

44 e, resulted in rapid apoptotic cell death in high-grade tumor cells resistant to the chemotherapeutic

45 expression was significantly more common in high grade tumors compared with low grade ones.

46 sensitive than (18)F-FDG to image recurrent high-grade tumors, correlated better with Ki-67 values,

47 EN-NHERF1-PHLPP1 tumor suppressor network in high-grade tumors, correlating with Akt activation and p

48 ition of ImmSig, spontaneously immortalizing high-grade tumor cultures displayed similar molecular ch

49 nked to outcome, with patients who developed high-grade tumors doing poorly and those who developed l

50 Finally, liver cancer organoid-generated high-grade tumors exhibited significantly increased extr

51 therapy for margins positive for tumor, for high-grade tumors, for improvement in local control, for

52 se of chemotherapy for synovial sarcoma, for high-grade tumors, for tumors larger than 10 cm, for pat

53 53ser246 mutation increases the incidence of high-grade tumors from 0% to 14% in HBsAg-negative, p53+

54 on volume and could separate newly diagnosed high-grade tumors from low-grade tumors.

55 and 93%, respectively, at the VOI level) and high-grade tumors from other tissue (AUCs of 85%, 79%, a

56 ue (BPH, prostatitis, or healthy tissue) and high-grade tumors from other tissue (low-grade tumors or

57 had low-grade tumors (G1 and G2) and 279 had high-grade tumors (G3 and G4).

58 carcinomas and tended to be more frequent in high grade tumors (Gleason grade 8 to 10; 41%) and nodal

59 disease progression [DP], 13%) versus 33% of high-grade tumors (grade 3 or 4) (complete response, 0%;

60 or sites, stage, sex, and age, patients with high-grade tumors had a significantly higher risk of VTE

61 After an early maximum, high-grade tumors had a steep descending branch, whereas

62 Patients with high-grade tumors had higher D-dimer levels (P = .008) a

63 High-grade tumors had significantly higher transport rat

64 ns and NNL, between HGG and LGG, and between high-grade tumor (HGG or lymphoma) and LGG or NNL.

65 Best differentiation between high-grade tumors (HGG or lymphoma) and both NNL and LGG

66 n nude mice led to growth of intermediate to high-grade tumors in 60-70% of mice.

67 lating factor-1 receptor (CSF-1R) to regress high-grade tumors in animal models of this cancer.

68 nsgenic murine models and is associated with high-grade tumors in patients.

69 High-grade tumors in the brain are among the deadliest o

70 in perfusion and metabolism between low- and high-grade tumors in the transgenic adenocarcinoma of mo

71 s in anaplastic large cell lymphoma and most high-grade tumors, including immunoblastic lymphomas, ex

72 d significantly improved survival at HVC for high-grade tumors (median 30 months vs. 24 months, P = 0

73 ated with at least one risk factor including high-grade tumor (n=4), prior surgery (n=5), radiation t

74 with 15 demonstrating risk factors including high-grade tumor (n=9) and prior surgery (n=10).

75 High-grade tumors (n = 85; 79%), age > 60 years (n = 61;

76 ephalic location (OR = 12.2, p = 0.013), and high-grade tumors (OR = 5.67, p = 0.013) were significan

77 ge (P = .01; HR, 1.04; 95% CI: 1.008, 1.08), high-grade tumor (P = .01; HR, 6.75; 95% CI: 1.44, 120.5

78 se (P < .001), pCR in the breast (P < .001), high-grade tumors (P < .001), and lower clinical and pat

79 High TR numbers were present in high-grade tumors (P < or = .001), in patients with lymp

80 F-FDOPA scans was seen between low-grade and high-grade tumors (P = 0.40) or between contrast-enhanci

81 cally significant prostate cancer, including high-grade tumors, primarily due to its effects on impro

82 High-grade tumors relapsed more frequently early during

83 High-grade tumors require multidisciplinary treatment co

84 In addition to advanced stage and high-grade tumors, several histopathological subtypes of

85 tly DCC positive (15 of 16, or 94%), whereas high-grade tumors significantly less often expressed the

86 esectable disease, incomplete resection, and high-grade tumors significantly reduced survival time.

87 traepithelial neoplasia and reappears in the high-grade tumors, suggesting a complex regulation of An

88 Kepsilon were associated with late-stage and high-grade tumors, suggesting a role of IKKepsilon in ov

89 E after 6 months was higher in patients with high-grade tumors than in those with low-grade tumors (8

90 African-American women had higher rates of high-grade tumors than white women regardless of screeni

91 Synovial sarcoma is a high-grade tumor that is associated with poor prognosis.

92 was a significant reduction in perfusion in high-grade tumors that associated with increased hypoxia

93 rvival rates (32% v 18%, P = .039) higher in high-grade tumors that did not express P-gp.

94 to tumor location and could not distinguish high-grade tumors that presented de novo from those that

95 -1 expression in both cell types was seen in high-grade tumors (tumor cells, P = 0.012; fibroblasts,

96 n the absence of the following risk factors: high-grade tumors, ventriculoperitoneal or ventriculoatr

97 The average fractional allele loss in the high-grade tumors was around 35%.

98 Average maximal lengths of low- and high-grade tumors were 7.7 and 15.0 cm, respectively.

99 survival rates for low-, intermediate-, and high-grade tumors were 75%, 62%, and 7%, respectively (P

100 40 +/- standard deviation, 7,703), all other high-grade tumors were hypermutant (mean, 1,589 +/- stan

101 Age < or = 50 years and high-grade tumors were significant factors (P = .003 and

102 eived finasteride had a greater incidence of high-grade tumors, which prohibited acceptance of finast

103 (18)F-FET uptake (TBR(max) < 2.5) excludes a high-grade tumor with high probability.

104 versus lesional tissue and low-grade versus high-grade tumors with 100% accuracy.

105 -grade characteristics, because treatment of high-grade tumors with a small molecule inhibitor of PDG

106 low differentiation of low-grade tumors from high-grade tumors with high metastatic potential.

107 derived growth factor-B (PDGF-B) resulted in high-grade tumors with MES features in a murine model of

108 eshold of 2.72 differentiated low-grade from high-grade tumors, with a sensitivity and specificity of

109 metabolic programs differentiating low- and high-grade tumors, with the metabolic signature of gliob

110 Nestin(Cre)Bax(fl/fl)Bak(-/-) mice harbored high-grade tumors within the testis, a peripheral site o